Bietti's Crystalline Dystrophy Clinical Trial
Official title:
A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of ZVS101e Administered as a Single Monocular Subretinal Injection in Subjects With Bietti's Crystalline Dystrophy (BCD)
The purpose of this study was to evaluate the safety and efficacy of ZVS101e administered by subretinal injection in subjects with Bietti's crystalline dystrophy (BCD) and to select the optimal effective dose.
This is a single-arm, open-label, and multi-center study of ZVS101e in patients with BCD. Up to 24 subjects are expected to be enrolled. Each participant will receive ZVS101e by subretinal injection in one eye on a single occasion. Safety, efficacy and vector shedding characteristics of ZVS101e are then measured over 180 days. Participants will subsequently enter a long-term follow-up study over a 4.5-year period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05714904 -
Safety and Tolerability of ZVS101e in Patients With Bietti 's Crystalline Dystrophy
|
Early Phase 1 | |
| Active, not recruiting |
NCT06302608 -
Safety and Efficacy Study of NGGT001 in Bietti Crystalline Corneoretinal Dystrophy
|
Early Phase 1 | |
| Recruiting |
NCT04722107 -
Safety Study of rAAV2/8-hCYP4V2 in Patients With Bietti's Crystalline Dystrophy (BCD)
|
Early Phase 1 |